Announcement • Aug 16
Innoveren Scientific Inc. announced delayed 10-Q filing On 08/15/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • May 18
Innoveren Scientific Inc. announced delayed 10-Q filing On 05/16/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Apr 03
Innoveren Scientific Inc. announced delayed annual 10-K filing On 04/02/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Mar 06
Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) Lite Innoveren Scientific Inc. announced that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product. SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product. Announcement • Nov 17
Innoveren Scientific Inc. announced delayed 10-Q filing On 11/15/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Aug 18
Innoveren Scientific Inc. announced delayed 10-Q filing On 08/16/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • May 16
H-CYTE, Inc. announced delayed 10-Q filing On 05/15/2023, H-CYTE, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Dec 30
H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown. H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown for $2.3 million on September 19, 2022. H-CYTE, Inc. (OTCQB: HCYT) entered into a definitive agreement to acquire SkinDisc from Tanya Rhodes and others on December 22, 2022. H-CYTE, Inc. will pay an aggregate of 123,153 shares and earn out payment of $1.615 million. Both parties board approved the transaction. The transaction is expected to close within the next 30 days. Arthur Marcus of Sichenzia Ross Ference acted as legal advisor to H-CYTE.
H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown on December 28, 2022. Announcement • Sep 20
H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc. H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc on September 19, 2022. The transaction is expected to close within the next 30 days. Announcement • Jan 12
H-CYTE, Inc. (OTCPK:HCYT) entered into a letter of intent to acquire Catheter Precision, Inc. H-CYTE, Inc. (OTCPK:HCYT) entered into a letter of intent to acquire Catheter Precision, Inc. on January 11, 2022. The transaction is subject to a definitive agreement and customary closing conditions. The transaction is expected to close in the first quarter of 2022. Announcement • Jun 30
H-CYTE, Inc. Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment at Helping Improve Overall Lung Health H-CYTE, Inc. announced the publication of its clinical observational study titled, 'Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.' The study, published in the peer-reviewed Journal of Regenerative Medicine & Biology Research, relates to the Company’s innovative autologous treatment, and concludes that patients experienced a statistically significant improvement in pulmonary function at both 3 months and 12 months (FEV1 % predicted) and quality of life (CCQ score) post treatment. The study, which involved 281 participants with COPD (chronic obstructive pulmonary disease). demonstrated that 23% of patients saw an improvement in their lung function by at least 15% from baseline at 3 months post-treatment(FEV1 measures), and 29% of patients saw the same improvement at 12 months post-treatment. At 3 months and 12 months post-treatment, 64% and 67% of participants respectively, experienced a significant quality of life improvement. All participants tolerated the procedure well, and there were no reportable adverse or unexpected events. All participants were able to stay on their physician prescribed medications to manage their COPD. The efficacy, quality of life and safety shown in this study were above and beyond that achieved with their maintenance therapy. The data came from an externally validated patient database. The study design was observational following the intervention and therefore the limitations due to lack of a control group are recognized. To address this, a double blind randomized controlled trial involving the Company’s innovative PRP-PBMC therapy is currently being planned. Announcement • Jan 21
H-Cyte, Inc. Announces Board Changes On January 12, 2021, Mr. William Horne stepped down as Chairman of the board of directors of H-Cyte, Inc. Mr. Horne will remain a member of the Board. On January 12, 2021, Mr. Ray Monteleone was appointed the new Chairman of the Board. Mr. Monteleone is a current member of the Board. Announcement • Oct 05
H-CYTE, Inc. announced that it expects to receive $5.515765 million in funding from FWHC Bridge, LLC, FWHC Bridge Friends, LLC H-CYTE, Inc. (OTCPK:HCYT) announced that it has entered into a secured convertible note and warrant purchase agreement with FWHC Bridge, LLC and FWHC Bridge Friends, LLC to issue two secured convertible promissory notes in the original principal amount of $1,000,000 and $1,535,570 to FWHC Bridge, LLC and a secured convertible promissory note in the original principal amount of $100,000 to FWHC Bridge Friends, LLC to receive $2.635,570 in debt in the transaction. The notes are convertible into shares of the company. The company will issue common shares and option, warrant or other right to acquire another security in the transaction to receive $2,880,195 in the transaction pursuant to regulation D. The minimum investment accepted from any outside investor is $1,875. The company will receive 5,515,765 in total in the transaction. Announcement • Oct 02
H-CYTE, Inc. announced that it has received $2.880195 million in funding from FWHC Bridge, LLC, FWHC Bridge Friends, LLC On May 5, 2020, H-CYTE, Inc. (OTCPK:HCYT) closed the transaction. The company amended the terms of the transaction. The company entered into a secured convertible note and warrant purchase agreement with FWHC Bridge, LLC and FWHC Bridge Friends, LLC. The company issued two secured convertible promissory notes in the original principal amount of $1,000,000 and $1,535,570 to FWHC Bridge, LLC and a secured convertible promissory note in the original principal amount of $100,000 to FWHC Bridge Friends, LLC to receive $2.635,570 in debt in the transaction. The notes are convertible into shares of the company. The company received $5,515,765 in the transaction. The transaction included participation from 32 investors pursuant to regulation D. Announcement • Oct 01
H-CYTE, Inc. Announces Executive Changes H-CYTE, Inc. appointed Mr. Robert Greif as its and President. Mr. Greif is 55 years old. Prior to joining the Company, Mr. Greif was the Chief Commercial Officer and business development Leader at Axos Bio, Inc. from February 2019 to November 2019. At Axos, Mr. Greif built the north American commercial organization in preparation for the launch of a fist-in-class immunomodulatory. Prior to joining Atox, Mr. Greif led the commercial operations of rEvo Biologics, Inc., an orphan disease biotechnology company from May 2011 to February 2019. He also held a variety of business unit and commercial leadership roles at United health Group Incorporated, Boehringer Ingelheim Group and Sanofi SA. The Company believes that Mr. Greif's strong track record leading high-growth pharmaceutical and biotech businesses makes him qualified to serve in his role with the Company. On September 29, 2020, Ann Miller resigned as the Company's Chief Operating Officer. On September 29, 2020, Mr. William Horne resigned as the Company's President. Announcement • Sep 30
H-CYTE, Inc. Announces Executive Changes H-CYTE, Inc. announced that Robert Greif has been named the company’s new chief executive officer. Most recently, he was Chief Commercial Officer and Business Development Leader at Atox Bio. Greif joins H-CYTE as CEO and President effective September 29, 2020. He replaces William E. Horne, who is stepping down as CEO but will remain on the company’s Board of Directors. 